Aurora Cannabis puede cambiar en 2023
Aurora Cannabis Inc. guiada por EBITDA ajustado positivo para el 31 de diciembre de 2022.
El plan de rentabilidad de la compañía de reducir los gastos de venta, generales y administrativos y centrarse en los ingresos de cannabis medicinal de alto margen está dando resultados.
Aurora Cannabis Inc. mantiene un sólido balance mientras se expande internacionalmente.
La tasa de disminución del precio de las acciones de Aurora Cannabis Inc. ( NASDAQ: ACB ) se desaceleró en la segunda mitad de 2022. Como era de esperar, las últimas semanas del año produjeron más disminuciones a medida que los inversores aprovecharon of tax loss harvesting.
During all this the company has continued to execute on the plan to profitability that was created back in the summer of 2021. The latest update on that plan guides for positive Adjusted EBITDA by the end of the year, which leaves only a few days. Previous management has also provided similar guidance in the past that was never met so investors are understandably jaded. The latest management, however, has been fairly conservative in this positive guidance, and I feel the CEO Miguel Martin has finally right-sized the company and moved it past its inflection point.
